-
公开(公告)号：KR1020140075662A
公开(公告)日：2014-06-19
申请号：KR1020140063999
申请日：2014-05-27
Applicant: 성균관대학교산학협력단
CPC classification number: A61K47/34 , A61K31/635
Abstract: The present invention relates to a eutectic composition comprising celecoxib and poloxamer. The eutectic composition comprising celecoxib and poloxamer according to one embodiment of the present invention includes celecoxib or pharmaceutically acceptable salt and block copolymer of poly (polyoxyethylene) and poly (Polyoxypropylene) and is manufactured by thermal melting.
Abstract translation: 本发明涉及包含塞来昔布和泊洛沙姆的共晶组合物。 根据本发明一个实施方案的包含塞来昔布和泊洛沙姆的共晶组合物包括塞来昔布或其可药用盐和聚（聚氧乙烯）和聚（聚氧丙烯）的嵌段共聚物，并且通过热熔制造。
-
公开(公告)号：KR1020130124113A
公开(公告)日：2013-11-13
申请号：KR1020120047766
申请日：2012-05-04
Applicant: 성균관대학교산학협력단
IPC: A61K9/08 , A61K47/48 , A61K31/44 , A61K31/404
CPC classification number: A61K47/10 , A61K31/635 , A61K47/40 , A61K9/08 , A61K31/404 , A61K31/44 , A61K47/50
Abstract: The present invention relates to an eutectic mixture having celecoxib with remarkably enhanced solubility and bioavailability through an eutetic reaction by adding poloxamer of chemical formula 2 to celecoxib of chemical formula 1 which is an insoluble drug. The weight ratio of poloxamer with respect to celecoxib is 3:7-6:4. More preferably, the eutectic mixture according to the present invention contains 1.5 parts by weight of poloxamer with respect to 1 part by weight of celecoxib. [Reference numerals] (AA) Temperature ;(BB) % celecoxib
Abstract translation: 本发明涉及一种具有塞来昔布的共晶混合物，其通过将化学式2的泊洛沙姆加入作为不溶性药物的化学式1的塞来昔布，通过可口反应显着提高溶解性和生物利用度。 泊洛沙姆相对于塞来昔布的重量比为3：7-6：4。 更优选地，根据本发明的共晶混合物相对于1重量份的塞来昔布含有1.5重量份泊洛沙姆。 （参考号）（AA）温度;（BB）％塞来昔布
-
公开(公告)号：KR1020130037802A
公开(公告)日：2013-04-17
申请号：KR1020110102243
申请日：2011-10-07
Applicant: 성균관대학교산학협력단
IPC: A61K9/28 , A61K31/428 , A61K47/38
CPC classification number: A61K9/28 , A61K9/2866 , A61K31/428 , A61K47/38
Abstract: PURPOSE: A sustained release fine particle containing pramipexole and a composition containing the same are provided to ensure a release-controlling effect by additional coating of ethyl cellulose. CONSTITUTION: A composition is a release-controlled formulation which is prepared by coating a sustained release fine particle containing pramipexole or a salt thereof with a coating solution containing ethyl cellulose. The sustained release fine particle contains pramipezole or a salt thereof and hydroxypropyl methylcellulose. [Reference numerals] (AA) Elution rate(%); (BB) Time(h); (CC) Bead weight ratio of before coating : after coating = 1 : 1.5; (DD) Bead weight ratio of before coating : after coating = 1 : 1.3;
Abstract translation: 目的：提供含有普拉克索的缓释微粒和含有它们的组合物，以通过额外涂布乙基纤维素来确保释放控制效果。 构成：组合物是通过用含有乙基纤维素的涂布溶液涂布含有普拉克索或其盐的缓释微粒制备的释放控制制剂。 持续释放的微粒含有丙胺嘧啶或其盐和羟丙基甲基纤维素。 （AA）洗脱率（％） （BB）时间（h）; （CC）涂布前的珠重比：涂布后= 1：1.5; （DD）涂布前的珠重比：涂布后= 1：1.3;
-
公开(公告)号：KR1020110104374A
公开(公告)日：2011-09-22
申请号：KR1020100023482
申请日：2010-03-16
Applicant: 성균관대학교산학협력단
IPC: A61K9/16 , A61K9/32 , A61K47/36 , A61K31/425
CPC classification number: A61K9/1652 , A61K9/1658 , A61K9/167 , A61K9/1682 , A61K31/428 , Y10S514/97
Abstract: 본 발명은 저장 안정성이 높은 프라미펙솔 디하이드로클로라이드(pramipexole dihydrochloride) 정제 및 이의 제조방법을 제공하기 위한 것이다.
-
公开(公告)号：KR101455901B1
公开(公告)日：2014-11-03
申请号：KR1020120047766
申请日：2012-05-04
Applicant: 성균관대학교산학협력단
IPC: A61K9/08 , A61K47/48 , A61K31/44 , A61K31/404
CPC classification number: A61K47/10 , A61K31/635 , A61K47/40
Abstract: 본 발명은 난용성 약물인 세레콕시브에 폴록사머를 첨가하여 공융 현상을 일으킴으로써, 용해도 및 생체이용률이 현저하게 증가된 세레콕시브를 제공하는 공융 혼합물에 관한 것이다.
-
Patent Agency Ranking
公开(公告)号：KR102009194B1
公开(公告)日：2019-08-09
申请号：KR1020170078441
申请日：2017-06-21
Applicant: 고려대학교 산학협력단 , 성균관대학교산학협력단
IPC: C12N1/20 , C12P3/00 , E02D3/12 , C12R1/01 , C04B103/00 , C04B111/72
-
公开(公告)号：KR1020130134353A
公开(公告)日：2013-12-10
申请号：KR1020120057807
申请日：2012-05-30
Applicant: 성균관대학교산학협력단
IPC: A61K9/14 , A61P1/04 , A61K31/4704
CPC classification number: A61K9/143 , A61K9/146 , A61K31/4704 , Y10S514/925
Abstract: The present invention relates to a pharmaceutical solid dispersion formulation for treatment of an ulcer and a preparing method thereof and, more particularly, to a pharmaceutical solid dispersion formulation for treatment of ulcer, capable of improving drug solubility and bioavailability, containing rebamipide, a water-soluble polymer, and a non-ionic surfactant. Thus, the present invention provides a method for preparing a solid dispersion formulation having improved drug solubility and bioavailability, so that the pharmaceutical formulation can have improved efficacy and thus be used for effective treatment of ulcer. [Reference numerals] (AA) Ulcer area(mm^2);(BB) Control group
Abstract translation: 本发明涉及用于治疗溃疡的药物固体分散体制剂及其制备方法，更具体地涉及能够改善药物溶解度和生物利用度的药物固体分散体制剂，其可用于治疗溃疡，其包含瑞巴派特， 可溶性聚合物和非离子表面活性剂。 因此，本发明提供了制备具有改进的药物溶解度和生物利用度的固体分散体制剂的方法，使得药物制剂可以具有改善的功效，因此用于有效治疗溃疡。 （AA）溃疡面积（mm ^ 2）;（BB）对照组
-
公开(公告)号：KR1020130003602A
公开(公告)日：2013-01-09
申请号：KR1020110065045
申请日：2011-06-30
Applicant: 성균관대학교산학협력단
CPC classification number: A61K9/1652 , A61K9/1617 , A61K9/1682 , A61K31/145 , A61K47/38
Abstract: PURPOSE: A sustained release microparticle composition containing tamsulosin, ethyl cellulose, and enteric polymer is provided to ensure sustained release and enteric properties. CONSTITUTION: A sustained release microparticle composition contains tamsulosin or a pharmaceutically acceptable salt thereof, ethyl cellulose, and enteric polymers. The enteric polymers are hydroxypropylmethyl cellulosephthalate, hydroxypropylmethyl cellulose acetatesuccinate, or methacrylic acid-acrylic acid ethyl copolymers. [Reference numerals] (AA) Released amount of medicine; (BB) Time(minutes); (CC) Comparative embodiment 4; (DD) Comparative embodiment 5; (EE) Embodiment 1; (FF) Embodiment 2; (GG) Embodiment 3
Abstract translation: 目的：提供含有坦索罗辛，乙基纤维素和肠溶性聚合物的持续释放微粒组合物，以确保持续释放和肠溶性。 构成：缓释微粒组合物含有坦索罗辛或其药学上可接受的盐，乙基纤维素和肠溶聚合物。 肠溶性聚合物是羟丙基甲基纤维素邻苯二甲酸酯，羟丙基甲基纤维素乙酸丁二酸酯或甲基丙烯酸 - 丙烯酸乙基共聚物。 （附图标记）（AA）药物释放量; （BB）时间（分钟）; （CC）比较实施例4; （DD）比较实施例5; （EE）实施例1; （FF）实施例2; （GG）实施例3
-
公开(公告)号：KR101420919B1
公开(公告)日：2014-07-16
申请号：KR1020120057807
申请日：2012-05-30
Applicant: 성균관대학교산학협력단
IPC: A61K9/14 , A61P1/04 , A61K31/4704
Abstract: 본 발명은 궤양 치료를 위한 약제학적 고체 분산체 제제 및 이의 제조방법에 관한 것으로, 더 상세하게는 레바미피드, 수용성 고분자 및 비이온성 계면활성제을 함유하는 약물 용해도 및 생체이용률을 향상시킨 궤양 치료를 위한 약제학적 고체 분산체 제제에 관한 것이다. 이에 따라, 약물의 용해도 및 생체이용률을 높인 고체 분산체 제제의 제조방법을 제공하며, 상기 방법으로 효능이 향상된 약제학적 제제를 효과적인 궤양 치료에 사용할 수 있다.
-
公开(公告)号：KR1020130009416A
公开(公告)日：2013-01-23
申请号：KR1020110070521
申请日：2011-07-15
Applicant: 성균관대학교산학협력단
IPC: A61K31/428 , A61K31/425 , A61K9/16 , A61K9/22
CPC classification number: A61K31/428 , A61K9/16 , A61K9/20 , A61K47/38
Abstract: PURPOSE: A sustained release microparticle containing pramipexole and ethyl cellulose and an orally fast disintegrating tablet containing the same are provided to maintain effective blood concentration and to improve drug compliance. CONSTITUTION: A sustained release microparticle of pramipexole contains 1 part by weight of pramipexole or a salt thereof and 13-33 parts by weight of ethyl cellulose. The salt is pramipexole hydrochloride. The viscosity of ethyl cellulose is 6-22 cp. An orally fast disintegrating tablet contains the sustained release granules, sugar alcohol, and a disintegrant. The orally fast disintegrating tablet contains 50-55 parts by weight of sugar alcohol based on 100 parts by weight of the sustained release granules. The orally fast disintegrating tablet additionally contains an excipient. [Reference numerals] (AA) Elution rate; (BB) Time(hour); (CC) Embodiment 3-1; (DD) Embodiment 3-2; (EE) Embodiment 3-3; (FF) Embodiment 3-4
Abstract translation: 目的：提供含有普拉克索和乙基纤维素的持续释放微粒和含有它的口服快速崩解片，以保持有效的血液浓度并改善药物依从性。 构成：普拉克索的缓释微粒含有1重量份的普拉克索或其盐和13-33重量份的乙基纤维素。 盐是普拉克索盐酸盐。 乙基纤维素的粘度为6-22厘泊。 口服快速崩解片含有缓释颗粒，糖醇和崩解剂。 口服快速崩解片剂基于100重量份的缓释颗粒含有50-55重量份的糖醇。 口服快速崩解片还含有赋形剂。 （附图标记）（AA）洗脱率; （BB）时间（小时）; （CC）实施例3-1; （DD）实施例3-2; （EE）实施例3-3; （FF）实施例3-4
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.02 seconds)
